GBGB1711677.3A
GB201711677D0
(en)
|
2017-07-20 |
2017-07-20 |
Combination treatment
|
HUE18715909A
HUE062729T2
(en)
|
2017-03-28 |
2018-03-28 |
Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
|
RS20230485A
RS64304B1
(en)
|
2017-03-28 |
2018-03-28 |
Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
|
PCT/GB2018/050822
WO2018178670A1
(en)
|
2017-03-28 |
2018-03-28 |
Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
|
FIEP18715909.0T
FI3600276T3
(en)
|
2017-03-28 |
2018-03-28 |
Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
|
SI201830944T
SI3600276T1
(en)
|
2017-03-28 |
2018-03-28 |
Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
|
ES18715909T
ES2950452T3
(en)
|
2017-03-28 |
2018-03-28 |
Betahistine, or a pharmaceutically acceptable salt thereof, and monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
|
DK18715909.0T
DK3600276T3
(en)
|
2017-03-28 |
2018-03-28 |
BETAHISTINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A MONOAMINOXIDASE INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF ONE OR MORE SYMPTOMS OF DIZZINESS IN AN INDIVIDUAL
|
PT187159090T
PT3600276T
(en)
|
2017-03-28 |
2018-03-28 |
Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
|
PL18715909.0T
PL3600276T3
(en)
|
2017-03-28 |
2018-03-28 |
Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
|
EP23176227.9A
EP4234022A3
(en)
|
2017-03-28 |
2018-03-28 |
Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
|
US16/499,087
US11083718B2
(en)
|
2017-03-28 |
2018-03-28 |
Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
|
EP18715909.0A
EP3600276B1
(en)
|
2017-03-28 |
2018-03-28 |
Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
|
HRP20230735TT
HRP20230735T1
(en)
|
2017-03-28 |
2018-03-28 |
Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
|
LTEPPCT/GB2018/050822T
LT3600276T
(en)
|
2017-03-28 |
2018-03-28 |
Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
|
US17/396,064
US11690830B2
(en)
|
2017-03-28 |
2021-08-06 |
Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
|
US18/320,761
US20230285373A1
(en)
|
2017-03-28 |
2023-05-19 |
Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
|